Payment overview · 2025
General Payments
$1,998.99
87 reported records · 28 companies
Healthcare provider profile · identity verified
Amit Ghose, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LANSING, MI · NPI 1639177686
Verified facts
What the public records show
CMS Open Payments records show Amit Ghose, MD received $1,998.99 in general payments during 2025 across 87 reported records.
Vanda Pharmaceuticals Inc. accounted for 12.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $247.46 | 12.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.96 | 9.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $171.81 | 8.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.81 | 8.2% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.13 | 8.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.11 | 8.0% | 11 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$154.81 | 7.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $118.89 | 6.0% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $95.76 | 4.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $78.90 | 4.0% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $77.88 | 3.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.81 | 2.2% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $34.25 | 1.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.33 | 1.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.01 | 1.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.30 | 1.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.21 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.62 | 1.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.87 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.30 | 0.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.28 | 0.9% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $16.97 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.00 | 0.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.87 | 0.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.67 | 0.8% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $15.58 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.57 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.83 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,998.99 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $247.46 | 8 | 2025 |
Source payment records
|
|||||
| ACTIVOS 10 BONE CEMENT Normalized: activos 10 bone cement |
Device | Medtronic, Inc. | $154.81 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.32 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $118.89 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $113.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.84 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $95.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.90 | 5 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $78.90 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $77.88 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $73.44 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.01 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.70 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.29 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.07 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $46.78 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.87 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.81 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.81 | 3 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $42.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.77 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.77 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.25 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.01 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.38 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.76 | 3 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $18.14 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $12.25 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $12.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 199 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 149 |
| Lisinopril | Lisinopril | 321 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 101 |
| Losartan Potassium | Losartan Potassium | 271 | 98 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 234 | 71 |
| Omeprazole | Omeprazole | 206 | 73 |
| Furosemide | Furosemide | 203 | 68 |
| Eliquis | Apixaban | 199 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 66 |
| Metformin Hcl | Metformin Hcl | 170 | 64 |
| Gabapentin | Gabapentin | 142 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 45 |
| Simvastatin | Simvastatin | 108 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 50 |
| Potassium Chloride | Potassium Chloride | 89 | 34 |
| Trazodone Hcl | Trazodone Hcl | 80 | 22 |
| Carvedilol | Carvedilol | 79 | 30 |
| Montelukast Sodium | Montelukast Sodium | 78 | 23 |
| Mounjaro | Tirzepatide | 77 | 18 |
| Ozempic | Semaglutide | 76 | 22 |
| Tramadol Hcl | Tramadol Hcl | 74 | 28 |
| Jardiance | Empagliflozin | 70 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 21 |
| Trulicity | Dulaglutide | 63 | 16 |
| Alprazolam | Alprazolam | 61 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 23 |
| Xarelto | Rivaroxaban | 61 | 15 |
| Meloxicam | Meloxicam | 56 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 17 |
| Sertraline Hcl | Sertraline Hcl | 55 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 20 |
| Allopurinol | Allopurinol | 52 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Alendronate Sodium | Alendronate Sodium | 45 | 21 |
| Azithromycin | Azithromycin | 43 | 31 |
| Farxiga | Dapagliflozin Propanediol | 42 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 15 |
| Finasteride | Finasteride | 38 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 15 |
| Ramipril | Ramipril | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 13 |
| Diazepam | Diazepam | 35 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 14 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 12 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 12 |
| Bumetanide | Bumetanide | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | 15 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 21 |
| Ibuprofen | Ibuprofen | 25 | 15 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | 12 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Nystatin | Nystatin | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,998.99 · 87 records | Vanda Pharmaceuticals Inc. | ABRYSVO, ACTIVOS 10 BONE CEMENT, AIRSUPRA, AREXVY, AVYCAZ, Auvelity, BREZTRI, Brinsupri, CAPLYTA, COMIRNATY, CREON, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, Flucelvax, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, RUKOBIA, Rybelsus, TEFLARO, TRELEGY ELLIPTA, TRINTELLIX, TRUMENBA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VRAYLAR, WATCHMAN FLX, Wegovy, XYOSTED, ZAVZPRET, ZENPEP, ZEPBOUND, ZERBAXA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error